Amy C. Foulkes

Salford, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 30 publications

The development of a risk threshold to aid risk stratified approach to monitoring for haematological, hepatic and/or renal adverse drug reactions during established cs DMARD treatment for systemic autoimmune rheumatic diseases: a RAND/UCLA Appropriateness Method consensus study.

The development of a risk threshold to aid risk stratified approach to monitoring for haematological, hepatic and/or renal adverse drug reactions during established cs DMARD treatment for systemic autoimmune rheumatic diseases: a RAND/UCLA Appropriateness Method consensus study.

Journal: Rheumatology (Oxford, England)

Published: August 04, 2025

The 2025 British Society for Rheumatology guideline for the prescription and monitoring of conventional synthetic disease-modifying anti-rheumatic drugs.

The 2025 British Society for Rheumatology guideline for the prescription and monitoring of conventional synthetic disease-modifying anti-rheumatic drugs.

Journal: Rheumatology (Oxford, England)

Published: May 08, 2025

Transcriptomic profiling and machine learning uncover gene signatures of psoriasis endotypes and disease severity.

Transcriptomic profiling and machine learning uncover gene signatures of psoriasis endotypes and disease severity.

Journal: Communications medicine

Published: January 14, 2025

Blood Single-Cell Transcriptomic and Proteomic Signatures of Paradoxical Eczema in Patients with Psoriasis Treated with Biologics.

Blood Single-Cell Transcriptomic and Proteomic Signatures of Paradoxical Eczema in Patients with Psoriasis Treated with Biologics.

Journal: The Journal of investigative dermatology

Published: July 08, 2024

The prescription and monitoring of conventional synthetic disease-modifying anti-rheumatic drugs: British Society for Rheumatology guideline scope.

The prescription and monitoring of conventional synthetic disease-modifying anti-rheumatic drugs: British Society for Rheumatology guideline scope.

Journal: Rheumatology advances in practice

Published: February 27, 2024

Risk of Paradoxical Eczema in Patients Receiving Biologics for Psoriasis.

Risk of Paradoxical Eczema in Patients Receiving Biologics for Psoriasis.

Journal: JAMA dermatology

Published: December 06, 2023

Integrated proteomics and genomics analysis of paradoxical eczema in psoriasis patients treated with biologics.

Integrated proteomics and genomics analysis of paradoxical eczema in psoriasis patients treated with biologics.

Journal: The Journal of allergy and clinical immunology

Published: February 20, 2023

Atopic Polygenic Risk Score Is Associated with Paradoxical Eczema Developing in Patients with Psoriasis Treated with Biologics.

Atopic Polygenic Risk Score Is Associated with Paradoxical Eczema Developing in Patients with Psoriasis Treated with Biologics.

Journal: The Journal of investigative dermatology

Published: November 08, 2022

The effect of immunomodulators on seroconversion after BNT162b2 and AZD1222 vaccines in patients with immune-mediated inflammatory diseases: a prospective cohort study.

The effect of immunomodulators on seroconversion after BNT162b2 and AZD1222 vaccines in patients with immune-mediated inflammatory diseases: a prospective cohort study.

Journal: The British journal of dermatology

Published: August 03, 2022

The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs.

The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs.

Journal: Rheumatology (Oxford, England)

Published: April 01, 2022

Executive summary: The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs.

Executive summary: The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs.

Journal: Rheumatology (Oxford, England)

Published: April 01, 2022

International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis.

International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis.

Journal: JAMA dermatology

Published: March 30, 2022

Showing 1-12 of 30

Last Updated: 09/26/2026